Merck: encouraging new results for Keytruda

(CercleFinance.com) - Merck announced yesterday that a Phase 3 trial of Keytruda met one of its two primary endpoints of disease-free survival (DFS) as adjuvant therapy for patients with certain non-small cell lung cancers (NSCLC).


As a result, adjuvant treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in DFS compared to placebo in the general population of patients with stage IB-IIIA NSCLC.

The company said that Keytruda has become fundamental to the treatment of metastatic non-small cell lung cancer and we continue to advance research to explore its potential to help fight cancer earlier.


Copyright (c) 2022 CercleFinance.com. All rights reserved.